摘要
目的:探讨吉西他滨联合顺铂治疗复发转移食管癌的疗效及安全性。方法:吉西他滨联合顺铂治疗70例复发或转移的食管鳞癌患者,记录其近期疗效,比较不同近期疗效患者的远期疗效及不良反应。结果:吉西他滨联合顺铂治疗复发转移食管癌患者的客观缓解率为31.43%,能显著延迟治疗有效患者的无进展生存期(progression-free survival,PFS),药物严重不良反应为血液毒性,但患者能耐受。结论:吉西他滨联合顺铂治疗复发转移食管癌具有一定的近期疗效和远期疗效,且安全可靠,值得临床推广。
Objective:To study the efficacy and safety of gemcitabine combined with cisplatin in recurrent and metastatic esophageal cancer.Methods:Gemcitabine combined with cisplatin was used to treat 70 patients with esophageal squamous cell carcinoma.The short-term efficacy was recorded and the long-term efficacy and toxicity of different short-term efficacy were compared.Results:The objective remission rate of gemcitabine combined with cisplatin in the treatment of recurrent and metastatic esophageal cancer was 31.43%.Progressive-free survival(PFS)was significantly delayed in patients with effective treatment.Severe side effects of the drug were hematotoxicity and patients could tolerate it.Conclusion:Gemcitabine combined with cisplatin in the treatment of recurrent and metastatic esophageal cancer has a certain short-term and long-term efficacy,and is safe and reliable,which is worthy of clinical promotion.
作者
刘华
冯永
蒋超
仲小敏
万一元
宋亚颀
LIU Hua;FENG Yong;JIANG Chao;ZHONG Xiaomin;WAN Yiyuan;SONG Yaqi(Department of Oncology,Huai'an First People's Hospital,Jiangsu Huai'an 223001,China)
出处
《现代肿瘤医学》
CAS
2020年第24期4284-4287,共4页
Journal of Modern Oncology
基金
南京医科大学科技发展基金项目(编号:NMUB2019338)。
关键词
吉西他滨
顺铂
复发转移
食管癌
gemcitabine
cisplatin
recurrent metastasis
esophageal cancer
